<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35945397</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease.</ArticleTitle><Pagination><StartPage>6254</StartPage><EndPage>6268</EndPage><MedlinePgn>6254-6268</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11312-7</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease (MND). The current gold-standard measure of progression is the ALS Functional Rating Scale-Revised (ALS-FRS(R)), a clinician-administered questionnaire providing a composite score on physical functioning. Technology offers a potential alternative for assessing motor progression in both a clinical and research capacity that is more sensitive to detecting smaller changes in function. We reviewed studies evaluating the utility and suitability of these devices to evaluate motor function and disease progression in people with MND (pwMND). We systematically searched Google Scholar, PubMed and EMBASE applying no language or date restrictions. We extracted information on devices used and additional assessments undertaken. Twenty studies, involving 1275 (median 28 and ranging 6-584) pwMND, were included. Sensor type included accelerometers (n&#x2009;=&#x2009;9), activity monitors (n&#x2009;=&#x2009;4), smartphone apps (n&#x2009;=&#x2009;4), gait (n&#x2009;=&#x2009;3), kinetic sensors (n&#x2009;=&#x2009;3), electrical impedance myography (n&#x2009;=&#x2009;1) and dynamometers (n&#x2009;=&#x2009;2). Seventeen (85%) of studies used the ALS-FRS(R) to evaluate concurrent validity. Participant feedback on device utility was generally positive, where evaluated in 25% of studies. All studies showed initial feasibility, warranting larger longitudinal studies to compare device sensitivity and validity beyond ALS-FRS(R). Risk of bias in the included studies was high, with a large amount of information to determine study quality unclear. Measurement of motor pathology and progression using technology is an emerging, and promising, area of MND research. Further well-powered longitudinal validation studies are needed.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9843-0778</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fawcett</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The School of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Zack</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forbes</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neurosciences, Psychology, School of Philosophy, Psychology and Language Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4276-639X</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082222" MajorTopicYN="N">Digital Technology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Devices</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Sensors</Keyword></KeywordList><CoiStatement>Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics. 
<b>Ethical standard statement</b>
. The authors confirm that this article complies with ethical standards.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35945397</ArticleId><ArticleId IdType="pmc">PMC9363141</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11312-7</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11312-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leighton DJ, et al. Changing epidemiology of motor neurone disease in Scotland. J Neurol. 2019;266(4):817&#x2013;825. doi: 10.1007/s00415-019-09190-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09190-7</ArticleId><ArticleId IdType="pubmed">30805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012 doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242. doi: 10.1093/braincomms/fcab242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, et al. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(5):381&#x2013;385. doi: 10.1136/jnnp-2016-314661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):300&#x2013;307. doi: 10.1080/21678421.2021.1879865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, et al. The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2013;6):351&#x2013;361. doi: 10.1080/21678421.2018.1440408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1440408</ArticleId><ArticleId IdType="pubmed">29451026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, et al. Using technology to improve access to specialist care in amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5&#x2013;6):313&#x2013;324. doi: 10.3109/21678421.2016.1165255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1165255</ArticleId><ArticleId IdType="pubmed">27027466</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AB, Nahed BV, Sheth KN. Mobile medical applications in neurology. Neurology. 2013;3(1):52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5765940</ArticleId><ArticleId IdType="pubmed">29406529</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12(1):1&#x2013;10. doi: 10.3109/17482968.2010.502940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.502940</ArticleId><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. J Neurol. 2019;266(10):2387&#x2013;2395. doi: 10.1007/s00415-019-09427-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09427-5</ArticleId><ArticleId IdType="pmc">PMC6765690</ArticleId><ArticleId IdType="pubmed">31187191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove S, et al. Accelerating clinical therapeutic trials in ALS through frequent at-home data collection. Neurology. 2020;94(15):4921.</Citation></Reference><Reference><Citation>Rutkove SB, et al. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol. 2020;7(7):1148&#x2013;1157. doi: 10.1002/acn3.51096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51096</ArticleId><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="pubmed">32515889</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Ann Clin Transl Neurol. 2019;6(5):873&#x2013;881. doi: 10.1002/acn3.770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.770</ArticleId><ArticleId IdType="pmc">PMC6529832</ArticleId><ArticleId IdType="pubmed">31139685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad N, et al. Reviews on various inertial measurement unit (IMU) sensor applications. Int J Signal Process Syst. 2013;1(2):256&#x2013;262. doi: 10.12720/ijsps.1.2.256-262.</Citation><ArticleIdList><ArticleId IdType="doi">10.12720/ijsps.1.2.256-262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13(5):439&#x2013;445. doi: 10.3109/17482968.2012.688837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.688837</ArticleId><ArticleId IdType="pmc">PMC3422377</ArticleId><ArticleId IdType="pubmed">22670883</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56(4):710&#x2013;715. doi: 10.1002/mus.25586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25586</ArticleId><ArticleId IdType="pubmed">28120413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossig C, et al. Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. J Neural Transm (Vienna) 2016;123(1):57&#x2013;64. doi: 10.1007/s00702-015-1439-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1439-8</ArticleId><ArticleId IdType="pubmed">26253901</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;536. doi: 10.7326/0003-4819-155-8-201110180-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-155-8-201110180-00009</ArticleId><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakers JN, et al. Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease. J Neurol. 2021;268(5):1738&#x2013;1746. doi: 10.1007/s00415-020-10366-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10366-9</ArticleId><ArticleId IdType="pmc">PMC8068646</ArticleId><ArticleId IdType="pubmed">33355879</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukenhorst AL, et al. Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS. Muscle Nerve. 2021;63(2):258&#x2013;262. doi: 10.1002/mus.27110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27110</ArticleId><ArticleId IdType="pmc">PMC7898508</ArticleId><ArticleId IdType="pubmed">33118628</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bie E, et al. Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1&#x2013;2):17&#x2013;23. doi: 10.1080/21678421.2016.1241278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1241278</ArticleId><ArticleId IdType="pubmed">27813421</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gancedo L, et al. Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth. 2019;7(12):e13433. doi: 10.2196/13433.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13433</ArticleId><ArticleId IdType="pmc">PMC6942190</ArticleId><ArticleId IdType="pubmed">31859676</ArticleId></ArticleIdList></Reference><Reference><Citation>Geronimo A, Martin AE, Simmons Z. Inertial sensing of step kinematics in ambulatory patients with ALS and related motor neuron diseases. J Med Eng Technol. 2021;45(6):486&#x2013;493. doi: 10.1080/03091902.2021.1922526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03091902.2021.1922526</ArticleId><ArticleId IdType="pubmed">34016013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly M, et al. The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):563&#x2013;573. doi: 10.1080/21678421.2020.1773501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1773501</ArticleId><ArticleId IdType="pubmed">32573278</ArticleId></ArticleIdList></Reference><Reference><Citation>Londral A et al (2013) A method to detect keystrokes using accelerometry to quantify typing rate and monitor neurodegenerative progression. In NEUROTECHNIX</Citation></Reference><Reference><Citation>Montero-Odasso M, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario neurodegenerative research initiative (ONDRI) J Alzheimers Dis. 2017;59(2):707&#x2013;721. doi: 10.3233/JAD-170149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170149</ArticleId><ArticleId IdType="pmc">PMC5523841</ArticleId><ArticleId IdType="pubmed">28671116</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, et al. Upper extremity 3-dimensional reachable workspace assessment in amyotrophic lateral sclerosis by Kinect sensor. Muscle Nerve. 2016;53(2):234&#x2013;241. doi: 10.1002/mus.24703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24703</ArticleId><ArticleId IdType="pmc">PMC4770889</ArticleId><ArticleId IdType="pubmed">25965847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1&#x2013;2):61&#x2013;67. doi: 10.1080/21678421.2018.1541095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1541095</ArticleId><ArticleId IdType="pmc">PMC6513689</ArticleId><ArticleId IdType="pubmed">30486680</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):555&#x2013;561. doi: 10.1080/21678421.2018.1510008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1510008</ArticleId><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevizan IL, et al. Efficacy of different interaction devices using non-immersive virtual tasks in individuals with Amyotrophic Lateral Sclerosis: a cross-sectional randomized trial. BMC Neurol. 2018;18(1):1&#x2013;10. doi: 10.1186/s12883-018-1212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1212-3</ArticleId><ArticleId IdType="pmc">PMC6296030</ArticleId><ArticleId IdType="pubmed">30558556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira FG, et al. A machine-learning based objective measure for ALS disease severity. NPJ Digit Med. 2022;5(1):1&#x2013;9. doi: 10.1038/s41746-022-00588-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-022-00588-8</ArticleId><ArticleId IdType="pmc">PMC8993812</ArticleId><ArticleId IdType="pubmed">35396385</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, et al. The Ontario neurodegenerative disease research initiative (ONDRI) Can J Neurol Sci. 2017;44(2):196&#x2013;202. doi: 10.1017/cjn.2016.415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.415</ArticleId><ArticleId IdType="pubmed">28003035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vert A, et al. Detecting accelerometer non-wear periods using change in acceleration combined with rate-of-change in temperature. BMC Med Res Methodol. 2022;22(1):147&#x2013;147. doi: 10.1186/s12874-022-01633-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01633-6</ArticleId><ArticleId IdType="pmc">PMC9123693</ArticleId><ArticleId IdType="pubmed">35596151</ArticleId></ArticleIdList></Reference><Reference><Citation>Godkin FE, et al. Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. J Neurol. 2022;269(5):2673&#x2013;2686. doi: 10.1007/s00415-021-10831-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10831-z</ArticleId><ArticleId IdType="pmc">PMC8548705</ArticleId><ArticleId IdType="pubmed">34705114</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser P, et al. Assessment of spatio-temporal gait parameters using inertial measurement units in neurological populations. Gait Posture. 2011;34(4):558&#x2013;560. doi: 10.1016/j.gaitpost.2011.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaitpost.2011.06.018</ArticleId><ArticleId IdType="pubmed">21764583</ArticleId></ArticleIdList></Reference><Reference><Citation>Londral A, Pinto S, de Carvalho M. Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clin Neurophysiol. 2016;127(1):925&#x2013;931. doi: 10.1016/j.clinph.2015.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2015.06.017</ArticleId><ArticleId IdType="pubmed">26160275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurillo G, et al. Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care. 2013;21(6):641&#x2013;656. doi: 10.3233/THC-130764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/THC-130764</ArticleId><ArticleId IdType="pubmed">24284552</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, et al. Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. Neuroimage. 2020;27:102312. doi: 10.1016/j.nicl.2020.102312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102312</ArticleId><ArticleId IdType="pmc">PMC7334468</ArticleId><ArticleId IdType="pubmed">32622315</ArticleId></ArticleIdList></Reference><Reference><Citation>Capecci M, et al. Clinical effects of robot-assisted gait training and treadmill training for Parkinson's disease. A randomized controlled trial. Ann Phys Rehabil Med. 2019;62(5):303&#x2013;312. doi: 10.1016/j.rehab.2019.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rehab.2019.06.016</ArticleId><ArticleId IdType="pubmed">31377382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijbels D, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler J. 2010;16(5):618&#x2013;626. doi: 10.1177/1352458510361357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458510361357</ArticleId><ArticleId IdType="pubmed">20207785</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451&#x2013;e460. doi: 10.1212/WNL.0000000000006855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. A road map for remote digital health technology for motor neuron disease. J Med Internet Res. 2021;23(9):e28766. doi: 10.2196/28766.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/28766</ArticleId><ArticleId IdType="pmc">PMC8495582</ArticleId><ArticleId IdType="pubmed">34550089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombaci A, et al. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci. 2021;42(1):9&#x2013;13. doi: 10.1007/s10072-020-04783-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04783-x</ArticleId><ArticleId IdType="pmc">PMC7538170</ArticleId><ArticleId IdType="pubmed">33025327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliese R, et al. Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces. J Neurol. 2022;269(6):2910&#x2013;2921. doi: 10.1007/s00415-022-10971-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-10971-w</ArticleId><ArticleId IdType="pmc">PMC8776511</ArticleId><ArticleId IdType="pubmed">35059816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanarayanan V, et al. Speech as a biomarker: opportunities, interpretability, and challenges. Perspect ASHA Special Interest Groups. 2022;7(1):276&#x2013;283. doi: 10.1044/2021_PERSP-21-00174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2021_PERSP-21-00174</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>